Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
Results from a clinical trial have revealed nearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after